It's not a paid ad but just wanted to let everyone know that if you’re wondering what I use to get my information for my research, it’s largely Koyfin. I use it daily and rely heavily on it to get the necessary information for my reports. If you’re interested in checking it out (highly recommend it), you can get 20% off your plan if you use my code here.

Quick Update

Hello everyone, I just wanted to quickly reassure everyone that while I’ve been covering Hims and Hers Health (HIMS) in-depth recently, including the Q2’24 update in this post, but I don’t want it to seem like that’s the only thing I’m lined up to write. There’s still plenty on my list and since I’m going on holiday in the middle of September for a few weeks, I’m sending you all a lot before then to make up for it.

On my list to send you all through the end of September and Q3/Q4 is listed below. It’s not an exhaustive list as it’s ever-changing but it’s what I have right now.

Additionally, I have one super quick question for you all. Suppose I started a podcast on behalf of Cedar Grove Capital talking about the businesses I write about. Would you want to receive them here (automatically sign up) or via a new distribution where you can decide if you want to sign up with no effect on your subscription here?

On to the programming.

Hims Q2’24 Post-Earnings Update

The recent earnings release from HIMS last Monday left many investors puzzled by the price action both before and after the earnings call. The days after were no help as the stock continued to drop, briefly breaking through $15 on Thursday.

I think a lot of assumptions as to “why” the stock dropped ranged from being an overreaction to a good print to run for the door. Considering my background working for the competition years ago, and recent coverage on the name, I believe I know what the market is “pricing in” and what many investors are left scratching their head.

Based on these findings, I think the future of HIMS had a justified re-evaluation after that call which I’ve gone ahead and included in the PDF below for all paid investors. The picture below is a teaser of the 12-page report for those who aren’t paying investors yet.

If you would like to look at my past work, you can access it via the Table of Contents. I would ask if you do like the update, please like the post and share it with your friends or fellow investors.

Cedar Grove Capital Management - Hims and Hers Health (HIMS) - Q2'24 Earnings Update.pdf

Cedar Grove Capital Management - Hims and Hers Health (HIMS) - Q2'24 Earnings Update.pdf

242.47 KBPDF File

Until next time,

Paul Cerro | Cedar Grove Capital

Personal Twitter: @paulcerro

Fund Twitter: @cedargrovecm

Disclaimer: I/we (“Cedar Grove Capital”) currently do have a stock, option, or similar derivative position in Hims and Hers Health (HIMS) at the time of writing this article.
All information provided herein by Cedar Grove Capital Management, LLC (“Cedar Grove Capital”) is for informational purposes only and does not constitute investment advice or an offer or solicitation to buy or sell an interest in a private fund or any other security. An offer or solicitation of an investment in a private fund will only be made to accredited investors pursuant to a private placement memorandum and associated documents.
Cedar Grove Capital may change its views about or its investment positions in any of the securities mentioned in this document at any time, for any reason or no reason. Cedar Grove Capital may buy, sell, or otherwise change the form or substance of any of its investments. Cedar Grove Capital disclaims any obligation to notify the market of any such changes.
The enclosed material is confidential and not to be reproduced or redistributed in whole or in part without the prior written consent of Cedar Grove Capital. The information in this material is only current as of the date indicated and may be superseded by subsequent market events or for other reasons. Statements concerning financial market trends are based on current market conditions, which will fluctuate. Any statements of opinion constitute only current opinions of Cedar Grove Capital which are subject to change and which Cedar Grove Capital does not undertake to update. Due to, among other things, the volatile nature of the markets, and an investment in the fund/partnership may only be suitable for certain investors. Parties should independently investigate any investment strategy or manager, and should consult with qualified investment, legal and tax professionals before making any investment.

Reply

Avatar

or to participate

Keep Reading